Using Gyrolab for HCP Analysis in Early Bioprocess Development
In the early stages of biopharmaceutical process development, it is critical to understand the behaviour of impurities. As process development progresses - generating more samples and accumulating knowledge through broad and targeted screening - a fast, sensitive and robust method for measuring product quality, such as host cell proteins (HCPs), is essential.
In this webinar, Martin Voigtmann from Boehringer Ingelheim RCV GmbH & Co KG discusses how Boehringer Ingelheim is using the Gyrolab platform as an orthogonal technology within a generic workflow to understand their processes with respect to HCPs, from process development to production scale.
BPI Spring Digital Week 2024
Martin Voigtmann Senior Scientist Analytical Development Boehringer Ingelheim RCV GmbH & Co KG,
